Day One Biopharmaceuticals

Yahoo Finance • last month

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mersana Therapeutics, Inc. (Nasdaq - MRSN), Cidara Therapeutics, Inc. (Nasdaq - CDTX), Cadence Bank (NYSE – CADE)

BALA CYNWYD, Pa., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 2 months ago

Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference

BRISBANE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of al... Full story

Yahoo Finance • 2 months ago

Key deals this week: Merck, Day One Biopharmaceutical, ABN AMRO, Revvity, Centerspace and more

Here's a list of key deals reported across sectors this week: Merck (MRK [https://seekingalpha.com/symbol/MRK]) to acquire [https://seekingalpha.com/pr/20307875-merck-to-acquire-cidara-therapeutics-inc-diversifying-its-portfolio-to-includ... Full story

Yahoo Finance • 2 months ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cidara Therapeutics, Inc. (Nasdaq - CDTX), Mersana Therapeutics, Inc. (Nasdaq - MRSN), TreeHouse Foods Inc. (NYSE - THS), Gulf Island Inc. (Nasdaq - GIFI)

BALA CYNWYD, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 2 months ago

Day One to buy Mersana Therapeutics for $25/share upfront

[Antibody drug conjugated with cytotoxic payload.] Love Employee/iStock via Getty Images Day One Biopharmaceuticals (DAWN [https://seekingalpha.com/symbol/DAWN]) has signed a definitive merger agreement to acquire clinical-stage biopharma... Full story

Yahoo Finance • 2 months ago

Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases

Acquisition expands Day One’s portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid cystic carcinoma type-1 (ACC-1), a can... Full story

Yahoo Finance • 2 months ago

Day One raises 2025 revenue guidance to $145M–$150M as OJEMDA sees sustained double-digit growth

Earnings Call Insights: Day One Biopharmaceuticals (DAWN) Q3 2025 MANAGEMENT VIEW * CEO Jeremy Bender highlighted Q3 as "an outstanding quarter for Day One," reporting "accelerated growth across every key dimension of OJEMDA's performa... Full story

Yahoo Finance • 3 months ago

Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025

BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages... Full story

Yahoo Finance • 5 months ago

Day one Biopharma general counsel sells $29k in shares

Adam Dubow, General Counsel & Secretary of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), sold 4,365 shares of common stock on August 18, 2025, at a weighted average price of $6.7671, for a total value of $29,538. The prices for these sha... Full story

Yahoo Finance • 5 months ago

Earnings call transcript: Day One Biopharma Q2 2025 revenue growth impresses

Day One Biopharmaceuticals (NASDAQ:DAWN) reported a robust financial performance for the second quarter of 2025, driven by strong revenue growth and strategic expansions. The company’s stock experienced a 2.15% increase in aftermarket trad... Full story

Yahoo Finance • 5 months ago

Day One Biopharmaceuticals Inc (NASDAQ:DAWN) Reports Q2 2025 Earnings: Revenue Growth but Wider-Than-Expected Loss

DAY ONE BIOPHARMACEUTICALS INC (NASDAQ:DAWN [https://www.chartmill.com/stock/quote/DAWN/profile]) REPORTS Q2 2025 EARNINGS: REVENUE GROWTH BUT WIDER-THAN-EXPECTED LOSS Day One Biopharmaceuticals Inc released its second-quarter 2025 financ... Full story

Yahoo Finance • 6 months ago

Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025

BRISBANE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages... Full story

Yahoo Finance • 7 months ago

Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadership to Day One Dr. Vasconcelles to drive pipeline creation and execution BRISBA... Full story

Yahoo Finance • 8 months ago

Day One Reports First Quarter 2025 Financial Results and Corporate Progress

OJEMDA™ (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™ (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in cash, cash equivalents and short-term... Full story

Yahoo Finance • 9 months ago

Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all age... Full story

Yahoo Finance • 11 months ago

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively Ended 2024 with $531.7 million in cash, cash equivalents and short-term investments Company to host conferenc... Full story

Yahoo Finance • 2 years ago

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

BRISBANE, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for peo... Full story

Yahoo Finance • 2 years ago

Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference

BRISBANE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for peo... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) (“Day One”) on behalf of the company’s investors. Since February 2023, shares of Day One’... Full story

Yahoo Finance • 2 years ago

INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Day One Biopharmaceuticals, Inc.; Urges Day One Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

STAMFORD, Conn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”) on behalf of the Company’s investors. The investigation seeks to determi... Full story